Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

ESMO 2019: Final FLAURA results reinforce front-line approval of AstraZeneca’s Tagrisso

AstraZeneca II
Final results from the Phase III FLAURA trial investigating AstraZeneca’s Tagrissofinal reinforce the therapy as the SOC for first-line treatment of patients with EGFRm advanced NSCLC, according to the study’s author.